The prompt use of rituximab could decrease adverse effects in patient with pemphigus vulgaris: A preliminary...

Area of Science:

• Dermatology
• Immunology

Background:

• Systemic corticosteroids are standard for pemphigus vulgaris (PV) but cause frequent adverse effects.
• Rituximab (RTX) is typically a second-line treatment for PV after other therapies fail.
• Early RTX administration may mitigate treatment-related adverse events.

Purpose of the Study:

• To evaluate the efficacy and safety of early rituximab (RTX) as a first-line treatment for pemphigus vulgaris (PV).
• To compare adverse effects in patients receiving early RTX versus traditional corticosteroid therapy.

Main Methods:

• A single-center study involving patients with predominantly oral PV.
• Treatment consisted of systemic corticosteroids and prompt intravenous RTX (1000 mg, two weeks apart).
• Clinical response and adverse effects were monitored for 24 months and compared to a historical control group.

Main Results:

• The study included 11 patients, compared to 98 in the control group.
• Complete clinical remission averaged 3.2 months; all study patients achieved remission without medication.
• Early RTX use reduced the likelihood of adverse effects by 94% (P = .001), with only 27.3% experiencing side effects.

Conclusions:

• This study presents the first report on RTX as a first-line therapy for oral PV.
• The proposed RTX regimen significantly minimizes adverse effects compared to corticosteroid-centered treatments.
• Further validation through multi-center randomized controlled trials is warranted.